ReviewJournal of medical ultrasonics (2001)2026
A review of my history of research on ultrasound tissue characterization of chronic liver disease for developing ultrasound clinical technology.
Review in Journal of medical ultrasonics (2001), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ultrasound echo signals from organs contain various physical information and numerous studies have been conducted to extract new diagnostic insights from these signals. This article reviews the research and development I have undertaken in diagnosing liver tissue characteristics, reflecting on its historical progression. Initially, texture analysis aimed to identify features of liver fibrosis, but it was found to be more effective for quantifying fatty liver. Consequently, the analysis algorithm and product specifications were refined to address this need. For fatty liver, the importance of early detection of non-alcoholic steatohepatitis (NASH) has grown, leading to investigations into quantifying the liver's attenuation coefficient. After several prototype trials, a real-time quantitative measurement function was achieved.
Indexed as
Identifiers
41498911What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.